Rasarfin is a dual Ras and ARF6 inhibitor.
In Vitro: Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation.
Rasarfin blocks GPCR internalization through inhibition of ARF6.
Rasarfin treatment results in a dose-dependent reduction in MDA-MB-231 cells.
Rasarfin inhibits the recruitment of the clathrin adaptor AP-2 to β-arrestin2 and receptor internalization, both processes that require active ARF6.